RxDoctor Payments Data

Talisha Hern, APRN

Family · Saint George, UTNPI 1275100703

Payments from drug & device makers

$3,021in general payments, 2019–2025

Across 144 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$543
  • Amgen$496
  • Novartis$273
  • AstraZeneca$241
  • Actelion Pharmaceuticals US, Inc.$237
  • Boston Scientific$232
  • plus $999 from 12 others

What the payments were for

  • Food & beverage$2,94698%
  • Education$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,021 in reported general payments places this provider in the 85th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Medicare billing

Part B allowed, 2024
$111,292
Medicare patients
436
Services billed
2,052

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban169$175,798
XareltoRivaroxaban47$59,988
EntrestoSacubitril/Valsartan14$24,054
Repatha PushtronexEvolocumab12$7,225
Metoprolol Succinate251$3,589
Losartan Potassium158$1,922
Atorvastatin Calcium158$1,762
Rosuvastatin Calcium130$1,526
Spironolactone102$1,104
Flecainide Acetate28$999
Amlodipine Besylate128$956
Calcitriol25$919
Amiodarone Hcl33$916
Potassium Chloride65$831
Metoprolol Tartrate58$748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$183$175,798169 claims
Johnson & JohnsonXarelto$184$59,98847 claims
NovartisEntresto$273$24,05414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,460 family providers in Utah.

Other family in Saint George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →